IFN-γ responses to recipient-derived PHA blasts and skin fibroblasts before and after immunizations (ELISPOT)
. | IFN-γ spots/106 PBMCs . | . | . | ||
|---|---|---|---|---|---|
| Pt/dosage and target* . | Before study . | After 3 injections . | After 6 injections . | ||
| 2/1 | |||||
| PHA blasts | 13 | 9 | 20 | ||
| SKF | 0 | 0 | 18 | ||
| 3/1 | |||||
| PHA blasts | 200 | 505 | 527 | ||
| SKF | 0 | 0 | 0 | ||
| 4/1 | |||||
| PHA blasts | 493† | 297 | 59 | ||
| SKF | 383† | 118 | 20 | ||
| 6/2 | |||||
| PHA blasts | NA | NA | NA | ||
| SKF | 18 | 67 | 32 | ||
| 7/2 | |||||
| PHA blasts | 10 | 485 | 370 | ||
| SKF | 0 | 60 | 90 | ||
| 8/3 | |||||
| PHA blasts | 0 | NA | 10 | ||
| SKF | 0 | NA | 146 | ||
. | IFN-γ spots/106 PBMCs . | . | . | ||
|---|---|---|---|---|---|
| Pt/dosage and target* . | Before study . | After 3 injections . | After 6 injections . | ||
| 2/1 | |||||
| PHA blasts | 13 | 9 | 20 | ||
| SKF | 0 | 0 | 18 | ||
| 3/1 | |||||
| PHA blasts | 200 | 505 | 527 | ||
| SKF | 0 | 0 | 0 | ||
| 4/1 | |||||
| PHA blasts | 493† | 297 | 59 | ||
| SKF | 383† | 118 | 20 | ||
| 6/2 | |||||
| PHA blasts | NA | NA | NA | ||
| SKF | 18 | 67 | 32 | ||
| 7/2 | |||||
| PHA blasts | 10 | 485 | 370 | ||
| SKF | 0 | 60 | 90 | ||
| 8/3 | |||||
| PHA blasts | 0 | NA | 10 | ||
| SKF | 0 | NA | 146 | ||
Patient 1 (dose level 1) experienced early disease progression. Patients 5 (dose level 2), 9 (dose level 3), and 10 (dose level 3) did not have enough blasts remaining for immunologic studies.
PBMCs indicates peripheral blood mononuclear cells; SKF, skin fibroblasts; and NA, not available.
Differences in IFN-γ secretion before and after immunization were not statistically significant whether patient-derived skin fibroblasts (P > .5) or PHA blasts (P > .345) were used as targets.
The dose-escalation schedule began at 2 × 105 CD40L-secreting skin fibroblasts per injection (dose level 1), increasing in log increments to 2 × 107 (dose level 3). IL-2-secreting skin fibroblasts and recipient-derived blasts were administered at a fixed dosage throughout the study (2 × 107 per injection)
No PBMCs available prior to 1 week after the first immunization for patient 4